Recombinant CD40L (Ruplizumab Biosimilar) 抗体
Quick Overview for Recombinant CD40L (Ruplizumab Biosimilar) 抗体 (ABIN5564228)
抗原
抗体类型
适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
特异性
- Recognizes and binds human CD40L with an IC50 of 0.845 μg/mL.
-
交叉反应
- 犬, 人
-
交叉反应 (详细)
- Cross-reacts with canine CD40L.
-
纯度
- >95 % (SDS-PAGE)
-
内毒素水平
- <0.001EU/μg
-
免疫原
- Recombinant human CD40L.
-
亚型
- IgG1
-
-
-
-
说明
-
This antibody is a biosimilar called Ruplizumab (Antova, BG9588) and originally developed by Biogen. Ruplizumab is a CD40 ligand blocker designed for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis, but withdrawn from clinical trials due to side effects.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- Lot specific
-
缓冲液
- In PBS.
-
储存液
- Without preservative
-
储存条件
- 4 °C,-20 °C
-
储存方法
-
Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C. Stable for at least 3 months after receipt when stored at +4°C. -
有效期
- 12 months
-
-
- CD40L (Ruplizumab Biosimilar) (CD40LG (Ruplizumab Biosimilar))
-
别名
- CD40L (Ruplizumab Biosimilar)
-
物质类
- Biosimilar
-
背景
- CD40 Ligand (CD40L), renamed TNFSF5 but now also known as CD154, TRAP and gp39, is a 34-39 kDa type II transmembrane glycoprotein, that belongs to the TNF superfamily, and a surface receptor expressed on activated T cells which acts as a costimulatory molecule to trigger immune responses. CD40L binds to CD40, which is essential in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development and germinal center formation. CD40 is constitutively expressed by antigen presenting cells, including dendritic cells, B cells and macrophages. Consistent with its widespread expression on normal cells, CD40 is also expressed on a wide range of tumor cells. CD40L levels are increased in serum and in inflamed tissues of patients with autoimmune diseases.
-
UniProt
- P29965
抗原
-